Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares traded up 13.1% on Wednesday . The company traded as high as C$3.56 and last traded at C$3.45. 5,663 shares were traded during trading, a decline of 24% from the average session volume of 7,410 shares. The stock had previously closed at C$3.05.
Eupraxia Pharmaceuticals Price Performance
The company’s 50-day simple moving average is C$2.80 and its 200-day simple moving average is C$2.72.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- Bank Stocks – Best Bank Stocks to Invest In
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3 Penny Stocks Ready to Break Out in 2025
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
